Goserelin plus endocrine treatments maintained long-term clinical benefit in a male patient with advanced breast cancer.

BACKGROUND

Goserelin plus aromatase inhibitors (AI) have already been used in male advanced breast cancer, but the cases that fulvestrantin male breast cancer are rare.

CASE PRESENTATION: Here we report a case of long-term (3 years) response to Goserelin plus continuing endocrine treatments given for a male advanced breast cancer. The patient prolongs his life with high life quality, and has more time with his family.

CONCLUSION

Goserelin plus endocrine treatments may benefit male breast cancer.